An Open Label Study to Evaluate G17DT Compared to Gemcitabine

NCT03200821 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL: G17DT
DRUG: Gemcitabine

Sponsor

Cancer Advances Inc.